摘要
过氧化物酶体增殖物激活受体(PPARs)是一类由配体激活的核转录因子,是非甾体类核受体超家族成员之一。根据其结构及功能的不同,可分为PPARα、PPARβ/δ及PPARγ3种亚型。既往的研究结果表明:PPARs可通过调节目的基因的表达参与脂肪代谢、糖代谢、炎症反应及机体对胰岛素敏感性的调节等多种重要生化反应及生物调节过程。近几年的研究结果表明:PPARs还具有抗纤维化、减轻组织缺血再灌注损伤以及影响肿瘤细胞生长与分化的效应。随着对肝脏疾病机制研究的不断深入,PPARs对其发生发展的调控机制也日益受到关注。笔者就近年来PPARs在肝脏疾病中的研究进展进行综述。
Peroxisome proliferator activated receptors(PPARs)are ligand activated nuclear transcription factors and one of the members of the non steroidal nuclear receptor superfamily.It can be divided into PPAR alpha,PPAR beta/delta and PPAR gamma three subtypes according to the different of its structure and function.Previous studies showed that PPARs participated in biochemical reactions and the regulation of other important biological activities such as lipogenesis,glucose metabolism,inflammation,insulin sensitivity and so on.Recent researches showed that PPARs also had effect of anti-fibrosis,protecting ischemia-reperfusion injury and inhibiting the growth and differentiation of tumor cells.This article reviewed the recent research progress of PPARs in these liver diseases.
作者
马盼飞
王超群
谷明旗
麻勇
Ma Panfei;Wang Chaoqun;Gu Mingqi;Ma Yong(Department of Hepatic Surgery,Key laboratory of Ministry of Education,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
出处
《中华消化外科杂志》
CAS
CSCD
北大核心
2019年第4期403-406,共4页
Chinese Journal of Digestive Surgery
基金
国家自然科学基金(81470876、81270527)
黑龙江省自然科学基金(LC2018037).
关键词
肝脏疾病
过氧化物酶体增殖物激活受体
机制
新进展
Liver disease
Peroxisome proliferator activated receptors
Mechanism
Research advance